Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6

Clin Chem Lab Med. 2023 Mar 30;61(10):1679-1687. doi: 10.1515/cclm-2022-1323. Print 2023 Sep 26.

Abstract

Over 3% of asthmatic patients are affected by a particularly severe form of the disease ("severe asthma", SA) which is often refractory to standard treatment. Airway remodeling (AR), which can be considered a critical characteristic of approximately half of all patients with SA and currently thought to be the main mechanism triggering fixed airway obstruction (FAO), seems to be a key factor affecting a patient's outcome. Despite the collective efforts of internationally renowned experts, to date only a few biomarkers indicative of AR and no recognizable biomarkers of lung parenchymal remodeling have been identified. This work examines the pathogenesis of airway and lung parenchymal remodeling and the serum biomarkers that may be able to identify the severe asthmatic patients who may develop FAO. The study also aims to examine if Krebs von den Lungen-6 (KL-6) could be considered a diagnostic biomarker of lung structural damage in SA.

Keywords: airway remodeling; asthma; biomarkers.

Publication types

  • Review

MeSH terms

  • Airway Obstruction* / complications
  • Airway Obstruction* / diagnosis
  • Asthma* / complications
  • Asthma* / diagnosis
  • Biomarkers
  • Humans
  • Lung Diseases, Interstitial*
  • Mucin-1

Substances

  • Biomarkers
  • Mucin-1